Abiopharma

🔍 GLENN JOHN (Executive)

Company: IRADIMED CORP (IRMD)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Sold 14,468 shares of Common Stock at $97.26 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,894.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 532 shares of Common Stock at $98.09 per share (Direct)
  Date: 2025-12-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,362.00 | transaction_form_type: 4
• Acquired 1,812 shares of Common Stock (Direct)
  Date: 2025-12-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 9,174.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Sold 714 shares of Common Stock at $97.38 per share (Direct)
  Date: 2025-12-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,460.00 | transaction_form_type: 4
• Sold 1,812 shares of Restricted Stock Units (Derivative)
  Date: 2025-12-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,624.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: This transaction was executed in multiple trades at prices ranging from $97.00 to $97.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F2: Restricted stock units convert into common stock on a one-for-one basis.
• F3: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.